Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goose parvovirus inactivated vaccine
- Development stage
- Unknown
- Lead developer
- Jinyu Youbang Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Goose parvovirus inactivated vaccine (TZ10 strain) is a veterinary biologic developed by Youbang Pharmaceutical for the prevention of gosling plague (also known as Derzsy's disease), a highly contagious and fatal disease affecting young goslings and Muscovy ducklings. The vaccine contains the inactivated TZ10 strain of Goose Parvovirus (GPV) propagated in susceptible embryos and formulated with an adjuvant (typically an oil emulsion) to stimulate a protective immune response. It is approved and marketed in China for veterinary use.
- Other names
- Derzsy's disease vaccineGosling plague vaccine小鹅瘟灭活疫苗(TZ10株)小鹅瘟灭活疫苗（TZ10株）
02
Targets
GPV (Goose parvovirus)
Beyond the preview
Go deeper on goose parvovirus inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goose parvovirus inactivated vaccine.